DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.

MLA

Sequera-Arquelladas, Sergio, et al. “DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.” Viruses, vol. 16, no. 2, Feb. 2024. EBSCOhost, https://doi.org/10.3390/v16020259.

APA

Sequera-Arquelladas, S., Hidalgo-Tenorio, C., López-Cortés, L., Gutiérrez, A., Santos, J., Téllez, F., Omar, M., Ferra-Murcia, S., Fernández, E., Javier, R., García-Vallecillos, C., & Pasquau, J. (2024). DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain. Viruses, 16(2). https://doi.org/10.3390/v16020259

Chicago

Sequera-Arquelladas, Sergio, Carmen Hidalgo-Tenorio, Luis López-Cortés, Alicia Gutiérrez, Jesús Santos, Francisco Téllez, Mohamed Omar, et al. 2024. “DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.” Viruses 16 (2). doi:10.3390/v16020259.